Association for Diagnostics & Laboratory Medicine elects new leaders
Dr. Stanley F. Lo, DABCC, FADLM, has been elected to serve on the ADLM board of directors as president-elect starting in August 2025
Dr. Stanley F. Lo, DABCC, FADLM, has been elected to serve on the ADLM board of directors as president-elect starting in August 2025
High Quality Assays with Reproducible and Reliable Results
TSKgel Amide-80 and TSKgel NH2-100 HILIC columns from Tosoh Bioscience are first class columns when it comes to separations of hydrophilic compounds like peptides, carbohydrates, polar natural substances, amino acids, oligonucleotides, organic polar acids and bases, even proteins.
SPEAR overcomes immunoassay complexity and sensitivity limitations in Alzheimer’s and neurodegenerative biomarker research with a homogeneous, wash-free format
Absolute characterization of protein-protein and other macromolecular interactions with composition-gradient multi-angle light scattering.
Fast, High-Sensitive Measurements through an Ultra-Compact Design

Fast, efficient and economical preparation of viable cell suspensions from small tissue samples
Waters has acquired technology assets and intellectual property rights of Megadalton Solutions, an early-stage developer of charge detection mass spectrometry (CDMS).
Automation-friendly solution delivers fast, reliable total RNA extraction for high-throughput and time-sensitive workflows
Last chance to vote for the products that have made the most difference to your research and be in with a chance to win a $100 Amazon Gift Card (or equivalent currency)
Collaboration to enable more streamlined end-to-end workflows while maintaining sample integrity
New funding accelerates platform development and meets surging demand as pharma and biotech reimagine drug discovery
The 2026 list highlights the pharmaceutical companies, biotechnology firms and CRDMOs are advancing decarbonization, green manufacturing and sustainable operations
Three therapeutic targets selected across high‑value clinical indications pipeline planned for four radiotherapy assets with in vivo data expected by end of 2026